Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...

In a report released yesterday, Robert Coolbrith from Evercore ISI maintained a Buy rating on Magnite (MGNI – Research Report), with a price ...

Julian Emanuel, Evercore ISI senior managing director, joins 'Fast Money' to talk the impact of tariffs, uncertainty, and ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

ESAB Corp (ESAB) stock fell about 2.7% over the past week, but Evercore ISI upgraded the stock to ‘In Line’ from ...

We recently published a list of 10 Best Performing Utilities Stocks So Far in 2025. In this article, we are going to take a ...

In this article, we are going to take a look at where Apple Inc. (NASDAQ:AAPL) stands against the other AI stocks. Tiger ...

Investing.com -- Evercore ISI added Wendy’s Co to its Tactical Outperform list ahead of the company’s investor day on March 6 ...

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

In the lead-up to Nvidia Inc.’s NVDA forthcoming earnings report after market close on Feb.26, Evercore ISI suggests that it is a good buying opportunity amid strong fundamentals. What Happened: In a ...